Table 2 Mechanism of lentinan in tumor diseases
From: Lentinan progress in inflammatory diseases and tumor diseases
Type of disease | Model | Mechanism | In vivo /in vitro | References |
|---|---|---|---|---|
Lung cancer | Human lung cancer cell | Enhance the activation of selective activation of Delta-like 1-Notch signaling | In vivo | Xu et al. 2022 [47] |
Lung cancer | Human lung cancer cell | Inhibited PVT1/miR-199a-5p/caveolin1 Pathway | In vivo | Qi et al. 2021 [50] |
Lung cancer | Human lung cancer cell | Regulate miR-216a-5p inhibited (JAK2/STAT3) signaling pathway | In vitro, in vitro, | Chen et al. 2021 [51] |
Lung cancer | Mouses models of lung cancer | Promote the expression of anti-vascular factor IFN-γ | In vivo, in vitro | Deng et al. 2018 [53] |
Lung cancer | Human experiment | Enhanced the immune function of CD4 and NK cells | In vitro | Zhu et al. 2022 [54] |
Lung cancer | Human experiment | Regulate CD4/CD8 ratio | In vivo, in vitro | Zhou et al. 2018 [55] |
Colon cancer | Mouses models of lung cancer | Endoplasmic reticulum stress autophagy | In vivo, in vitro | Zhang et al. 2021 [59] |
Colon cancer | Mouses models of lung cancer | Promote the expression of TNF-α Promote mitochondrial membrane potential loss | In vivo, in vitro | Wang et al. 2017 [61] |
Colorectal cancer | Mouses models of lung cancer | Reduce the expression of antitumor factors TNF-α to promote the transformation of M1 cells into M2 cells | In vivo, in vitro | Mao et al. 2022 [62] |
Colorectal cancer | Human experiment | Regulate CD4/CD8 ratio | In vivo | Chen et al. 2019 [63] |
Colorectal cancer | Human experiment | Regulate CD4/CD8 ratio | In vivo | Tu et al. 2010 [64] |
Liver cancer | Mouses models of liver cancer | Regulate EGR1/PTEN/AKT signaling | In vivo, in vitro | You et al. 2023 [68] |
Liver cancer | Mouses models of liver cancer | Regulate Apaf1 apoptosis | In vivo, | Wang et al. 2021 [70] |
Liver cancer | Mouses models of liver cancer | Activate the intrinsic apoptosis pathway Inhibition of NF-κB | In vivo, in vitro | Xu et al. 2022 [71] |
Liver cancer | Mouses models of liver cancer | Activate hepatocyte immune function and anti-tumor activity, | In vivo, | Wang et al. 2015 [72] |
Liver cancer | Human experiment | rRaeduce IL-12 | In vivo, | Nan et al. 2018 [74] |
Liver cancer | Human experiment | Reduce the expression of vascular endothelial growth factor | In vivo, | Zhao, 2015 [75] |
Gastric cancer | Human experiment | Increase NK cells and reduce IL-6 | In vivo, | Wang et al. 2018 [81] |
Gastric cancer | Human experiment | Regulate CD4/CD8 ratio | In vivo, | Yan et al. 2008 [82] |
Osteosarcoma | Mouses models | Regulate ERK/MAPK signaling pathway | in vivo, | Fan et al. 2021 [84] |
Esophageal cancer | Mouses models | Promote apoptosis | In vivo, | Huo et al. 2022 [86] |
Esophageal cancer | Human experiment | IL-5, IL-10, and IL-2 levels decrease | In vivo, | Wang et al. 2012 [87] |
Bladder cancer | Mouses models | Promote apoptosis | In vivo, | Sun et al. 2015 [89] |
Human-oral squamous cell carcinoma | Cell | Up-regulate the expression of OPRT mRNA | In vivo,in vitro | Harada et al. 2010 [90] |